• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLS alert in real time by email
    SC 13G/A 1 deeptrack-apls111524a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Apellis Pharmaceuticals Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    03753U106

    (CUSIP Number)

     

     

    November 20, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  03753U106
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Capital, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,000,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,000,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,000,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.82%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  03753U106
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Biotechnology Master Fund, Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,000,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,000,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,000,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.82%
    12
    TYPE OF REPORTING PERSON
     
    CO

     


     

    CUSIP No.  03753U106
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    David Kroin
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,000,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,000,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,000,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.82%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC
     


     

     

    CUSIP No. 03753U106
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Apellis Pharmaceuticals Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    100 Fifth Avenue

    Waltham, MA 02451

    Item 2.(a) Names of Persons Filing:

    (i) Deep Track Capital, LP

    (ii) Deep Track Biotechnology Master Fund, Ltd.

    (iii) David Kroin 

      

    Item 2.( b) Address of Principal Business Office:

    (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

    (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands

    (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

      

    Item 2.(c) Citizenship:

    (i) Delaware

    (ii) Cayman Islands

    (iii) United States

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.0001 par value per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    03753U106

     

    CUSIP No.  03753U106
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

     

     

     

     

    CUSIP No. 03753U106
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of November 22, 2024, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    The amount beneficially owned by each Reporting Person is determined based on 124,393,017 Common Stock outstanding as of October 29, 2024, according to the issuer’s Form 10-Q filed with the SEC on November 5, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 03753U106
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 22, 2024

     

     

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
     
    CUSIP No. 03753U106
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 22, 2024

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
    Get the next $APLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APLS

    DatePrice TargetRatingAnalyst
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    4/29/2025$44.00Overweight
    Cantor Fitzgerald
    12/17/2024$36.00Buy → Neutral
    Goldman
    11/21/2024$31.00Equal-Weight
    Morgan Stanley
    10/25/2024$25.00Sector Perform
    RBC Capital Mkts
    10/16/2024Sector Outperform
    Scotiabank
    10/16/2024Outperform
    William Blair
    More analyst ratings

    $APLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Apellis Announces Craig Wheeler to Join the Board of Directors

      WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. "We are thrilled to welcome Craig to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines

      4/21/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apellis Announces Keli Walbert to Join the Board of Directors

      WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c

      1/10/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 4:16:13 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

      SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 8:47:59 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/14/24 1:28:32 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

      Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $358.4 million as of March 31, 2025;

      5/7/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

      WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. PTStifel 2025 Virtual Ophthalmology Forum: Fireside chat on Tuesday, May 27, 2025 at 2:30 p.m. ET The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical compan

      5/6/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines co

      4/30/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.

      10-Q - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      5/7/25 7:01:36 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Apellis Pharmaceuticals Inc.

      DEFA14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      4/23/25 7:35:44 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Apellis Pharmaceuticals Inc.

      DEF 14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      4/23/25 7:33:44 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apellis Pharmaceuticals downgraded by Raymond James with a new price target

      Raymond James downgraded Apellis Pharmaceuticals from Strong Buy to Outperform and set a new price target of $52.00

      5/9/25 8:40:54 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals downgraded by BofA Securities with a new price target

      BofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $23.00

      5/9/25 8:40:54 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00

      4/29/25 8:10:45 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wheeler Craig A was granted 16,483 shares (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      4/21/25 4:23:01 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Wheeler Craig A

      3 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      4/21/25 4:09:13 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP/Chief Accounting Officer Chopas James George sold $4,543 worth of shares (183 units at $24.82), decreasing direct ownership by 0.38% to 47,955 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      3/18/25 12:27:02 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    Financials

    Live finance-specific insights

    See more
    • Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

      Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $358.4 million as of March 31, 2025;

      5/7/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines co

      4/30/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

      Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 million Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $411.3 million as of December 31, 2024; projected revenues and cash expected to be sufficient to fund operations to p

      2/28/25 7:05:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

      Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

      5/17/21 11:09:40 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care